Literature DB >> 34329777

Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.

Sharmistha Rudra1, Eliana Shaul1, Maire Conrad2, Trusha Patel2, Astrela Moore3, Noor Dawany4, Megan C Canavan1, Kathleen E Sullivan5, Edward Behrens6, Judith R Kelsen7.   

Abstract

Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD1; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34329777      PMCID： PMC8792097          DOI： 10.1016/j.cgh.2021.07.040

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   13.576


  8 in total

1.  Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.

Authors:  Rotraut Mössner; Nina Diering; Oliver Bader; Susann Forkel; Tobias Overbeck; Uwe Gross; Bodo Grimbacher; Michael P Schön; Timo Buhl
Journal:  Clin Infect Dis       Date:  2016-01-19       Impact factor: 9.079

2.  North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease.

Authors:  Judith R Kelsen; Kathleen E Sullivan; Shervin Rabizadeh; Namita Singh; Scott Snapper; Abdul Elkadri; Andrew B Grossman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-03       Impact factor: 2.839

Review 3.  JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.

Authors:  Azucena Salas; Cristian Hernandez-Rocha; Marjolijn Duijvestein; William Faubion; Dermot McGovern; Severine Vermeire; Stefania Vetrano; Niels Vande Casteele
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-19       Impact factor: 46.802

4.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.

Authors:  Julie Toubiana; Satoshi Okada; Julia Hiller; Matias Oleastro; Macarena Lagos Gomez; Juan Carlos Aldave Becerra; Marie Ouachée-Chardin; Fanny Fouyssac; Katta Mohan Girisha; Amos Etzioni; Joris Van Montfrans; Yildiz Camcioglu; Leigh Ann Kerns; Bernd Belohradsky; Stéphane Blanche; Aziz Bousfiha; Carlos Rodriguez-Gallego; Isabelle Meyts; Kai Kisand; Janine Reichenbach; Ellen D Renner; Sergio Rosenzweig; Bodo Grimbacher; Frank L van de Veerdonk; Claudia Traidl-Hoffmann; Capucine Picard; Laszlo Marodi; Tomohiro Morio; Masao Kobayashi; Desa Lilic; Joshua D Milner; Steven Holland; Jean-Laurent Casanova; Anne Puel
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

5.  Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

Authors:  Lisa R Forbes; Tiphanie P Vogel; Megan A Cooper; Johana Castro-Wagner; Edith Schussler; Katja G Weinacht; Ashley S Plant; Helen C Su; Eric J Allenspach; Mary Slatter; Mario Abinun; Desa Lilic; Charlotte Cunningham-Rundles; Olive Eckstein; Peter Olbrich; R Paul Guillerman; Niraj C Patel; Yesim Y Demirdag; Christa Zerbe; Alexandra F Freeman; Steven M Holland; Paul Szabolcs; Andrew Gennery; Troy R Torgerson; Joshua D Milner; Jennifer W Leiding
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

6.  Ruxolitinib Response in an Infant With Very-early-onset Inflammatory Bowel Disease and Gain-of-function STAT1 Mutation.

Authors:  Karen P Acker; Rachel Borlack; Alina Iuga; Helen E Remotti; Craig R Soderquist; Satoshi Okada; Miyuki Tsumura; Jean-Laurent Casanova; Joseph Picoraro; Anne Puel; Sivan Kinberg; Yesim Demirdag
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-10       Impact factor: 2.839

Review 7.  The diagnostic approach to monogenic very early onset inflammatory bowel disease.

Authors:  Holm H Uhlig; Tobias Schwerd; Sibylle Koletzko; Neil Shah; Jochen Kammermeier; Abdul Elkadri; Jodie Ouahed; David C Wilson; Simon P Travis; Dan Turner; Christoph Klein; Scott B Snapper; Aleixo M Muise
Journal:  Gastroenterology       Date:  2014-07-21       Impact factor: 33.883
  8 in total
  1 in total

Review 1.  New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease.

Authors:  Qi-Qi Li; Hui-Hong Zhang; Shi-Xue Dai
Journal:  Front Pediatr       Date:  2022-03-01       Impact factor: 3.418
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.